LYON, France--(BUSINESS WIRE)--Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 - ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, announced today that on November 2nd 2016 it received both the First prize for ‘Profitable Growth’ and the Third Prize ‘Technology Fast 50’ for the Grand Rhône Alpes Region as part of the Deloitte In Extenso Technology Fast 50 16th annual event in Lyon.
The Deloitte In Extenso Technology Fast 50 honours high-growth, technology-focused companies that invest at least 5% of their revenues in R&D in one of the 6 following sectors: Biotech, Energy, Electronics, Media & Telecommunication, Software & IT, Aerospace & Defence. Companies are ranked according to the growth of their revenues during the four previous years. Adocia, a company dedicated to medical innovation, invested 80% of its budget in R&D in 2015 and increased its turnover from €4m to €37m in the past 4 years.
« Technology Fast 50 shines a light on companies like Adocia, who are the quintessential examples of the incredible drive of French entrepreneurs for innovation and value creation. As it reaches its 16th edition, the French Technology Fast 50 ranking has become a reference for French and international investors. We are proud that Adocia is amongst the 2016 laureates. » commented Laurent Halfon, Deloitte Partner in charge of the Technology Fast 50.
« After receiving the Biotech Rising Star Award three years ago and the Listed Company Award last year, we are honoured that Deloitte In Extenso continues to recognize our company and strategy with these two Technology Fast 50 Awards,” said Olivier Soula, Deputy General Manager and R&D Director at Adocia. “We especially wish to congratulate our team for their daily commitment to serve the needs of patients living with diabetes and to thank our investors who have put their trust in us since the foundation of the company.”
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia’s insulin formulation portfolio, featuring four clinical-stage products and one preclinical product, is among the largest and most differentiated in the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia’s clinical pipeline includes four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of basal insulin glargine and rapid-acting insulin lispro (BioChaperone Combo). Adocia is also developing an aqueous formulation of human glucagon (BioChaperone Human Glucagon), two combinations of insulin glargine with GLP-1s (BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide) and a concentrated, rapid-acting formulation of human insulin (HinsBet U500), all of which are in preclinical development.
In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro projects.
Adocia aims to deliver “Innovative medicine for everyone, everywhere.”
To learn more about Adocia, please visit us at www.adocia.com
About the Technology Fast 50 programme
The Technology Fast 50 program started in 1995 in San Jose, California, at the heart of the Silicon Valley, and was extended to the entire United States and then to the United Kingdom, Canada, the Netherlands, Israel and France. It is now present in more than 40 countries and regions around the world. It was created in order to recognize the outstanding contribution of technological companies to the growth of the economy.
Deloitte has also developed three continental competitions: Europe, Middle East and Africa : Fast 500 EMEA ; North America : Fast 500 North America ; Asia Pacific : Fast 500 Asia Pacific.
To learn more, visit www.fast50france.com
Deloitte refers to one or more member companies of Deloitte Touche Tohmatsu Ltd, a UK private company limited by guarantee (“DTTL”) and its network of member companies, each of which is a legally separate and independent entity. To learn more about the legal structure of Deloitte Touche Tohmastu Ltd and its member companies, visit www.deloitte.com/about.
In France, Deloitte SAS is the member company of Deloitte Touche Tohmatsu Ltd, and the professional services are provided by its subsidiaries and affiliates.
© 2016 Deloitte SAS, Membre de Deloitte Touche Tohmatsu Limited
About In Extenso
In Extenso, a Deloitte company, is a key actor providing accounting and financial services to French SMEs. With a network of more than 4 900 collaborators and 220 offices spread over the territory, In Extenso proposes to entrepreneurs, artisans, retail traders, liberal professions and association executives full professional services, at all the stages of the company’s life and in all domains related to their activity’s management: accounting, tax, management, legal, social and payroll support, real estate, innovation, damages evaluation, legal redress, tourism advisory services, culture and hotel management, business transfer. In Extenso is the privileged interlocutor of more than 100,000 customers in all business sectors. In Extenso realized in 2015-2016 a turnover of €370 million.
This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the ‘Risk Factors’ section of the Reference Document filed with the French Autorité des marchés financiers on April 8, 2016 (a copy of which is available on www.adocia.com) and to the development of economic conditions, financial markets and the markets in which Adocia operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not currently considered material by Adocia. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Adocia to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia shares in any jurisdiction.